The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,781,522 in first-year total cost, median $442,618.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-F (50)]10
- Special Emphasis Panel[ZRG1 EMNR-H (50)]4
Most frequent institutions
- GEORGIA STATE UNIVERSITY2
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2
- BAYLOR COLLEGE OF MEDICINE1
- BOSTON MEDICAL CENTER1
- CASE WESTERN RESERVE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury1R01DK128823-01A1 | DE CAESTECKER, MARK P.OTTERBEIN, LEO EWANG, BINGHE | GEORGIA STATE UNIVERSITY, GA | $750,347 | ZRG1 |
| 2022 | Targeting POGLUT1 to promote biliary development in Alagille syndrome1R01DK132751-01 | HUPPERT, STACEY SJAFAR-NEJAD, HAMED | BAYLOR COLLEGE OF MEDICINE, TX | $400,001 | ZRG1 |
| 2022 | Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD1R01DK130094-01A1 | DEVITA, ROBERT JPETER, INGA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $399,978 | ZRG1 |
| 2022 | Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment1R01DK130174-01A1 | WANG, WEIDONG | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $395,452 | ZRG1 |
| 2022 | Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease1R01DK133903-01 | SUBAUSTE, CARLOS S | CASE WESTERN RESERVE UNIVERSITY, OH | $354,200 | ZRG1 |
| 2022 | New Therapeutic Leads for Proteinuric Kidney Diseases1R01DK133940-01 | LU, WEINING | BOSTON MEDICAL CENTER, MA | $267,000 | ZRG1 |
| 2021 | Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment1R01DK126080-01A1 | FARRIS, ALTON BLIU, ZHI-RENYANG, JENNY J. | GEORGIA STATE UNIVERSITY, GA | $614,398 | ZRG1 |
| 2021 | Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)1R01DK128819-01 | BOUDINA, SIHEMMIMCHE, PATRICE | UNIVERSITY OF UTAH, UT | $599,884 | ZRG1 |
| 2021 | Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment1R01DK128848-01 | QIANG, LIWANG, WEIDONG | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $476,180 | ZRG1 |
| 2021 | Optimizing small molecule SWELL1-LRRC8 modulators to treat Type 2 diabetes1R01DK126068-01A1 | SAH, RAJAN | WASHINGTON UNIVERSITY, MO | $423,936 | ZRG1 |
| 2020 | Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications1R01DK122456-01A1 | RAMASAMY, RAVICHANDRANSCHMIDT, ANN MARIE | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $672,000 | ZRG1 |
| 2020 | Development of long-acting glucose-responsive insulin formulations1R01DK121336-01A1 | CHOU, DANNY HUNG-CHIEH | STANFORD UNIVERSITY, CA | $643,846 | ZRG1 |
| 2020 | Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy1R01DK123712-01A1 | MATOBA, NOBUYUKI | UNIVERSITY OF LOUISVILLE, KY | $461,300 | ZRG1 |
| 2020 | SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis1R01DK126070-01 | CIL, ONUR | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $323,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.